Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-31 @ 9:56 AM
Study NCT ID:
NCT04162756
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-10-14
First Post:
2019-11-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Sponsor:
Kite, A Gilead Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2019-11-11
First Submit QC Date:
None
Study First Post Date:
2019-11-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-06
Last Update Post Date:
2021-10-14
Last Update Post Date Type:
ACTUAL